Clinical Trial

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Our study is aimed to evaluate the efficacy and safety of novel ADCs named SHR-A1811, SHR-A1921 and SHR-A2102 combined with adebrelimab in HER2-negative advanced breast cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-28.
Status change: Not Yet Recruiting → Recruiting 2026-07-13
Trial Details
NCT Number NCT06433609
Lead Sponsor Beijing GoBroad Hospital
Conditions Advanced Breast Cancer
Enrollment 113 participants
Start Date 2024-08-05
Primary Completion 2027-03 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-14